2017 New Drug Update Tom Frank, Pharm.D., BCPS Director of Research and Education UAMS Northeast
|
|
- Noah Alexander
- 6 years ago
- Views:
Transcription
1 2017 New Drug Update Tom Frank, Pharm.D., BCPS Director of Research and Education UAMS Northeast Zurampic (lesinurad) Ironwood Lesinurad I have no conflicts of interest to report Indicated for reducing uric acid in combination with a xanthine oxidase inhibitor in patients who are not at target with XOI only Reduces uric acid levels by inhibiting function of transporter proteins in uric acid reabsorption in the kidney Objectives Lesinurad Discuss trends in drug development Describe indications, pharmacology, adverse effects, and dosing of the products discussed Compare these products with other similar products in the participant s practice Bioavailability 100% Peak concentration 1 4 hours after dosing 98% protein bound Metabolism by CYP 2C9 to inactive metabolites Half life 5 hours No dose adjustment needed for mild moderate renal impairment; do not initiate if CrCl < 45ml/min Drug interactions: CYP 2C9 inhibitors and inducers, sildenafil, amlodipine, colchicine, avoid valproate, ocp s less effective, limit aspirin 1
2 Lesinurad Lesinurad Compared to placebo in randomized, double blind study over 12 months All patients got allopurinol but inadequate response Compared lesinurad 200mg, 400mg and placebo daily Primary end point: uric acid 6.5mg/dl End point reached in 54%, 59% and 27% Gout flare rate and tophus dissolution rate not different between groups 200mg once daily used in combination with a xanthine oxidase inhibitor Take in the morning with food or water Discontinue if CrCl drops below 45ml/min Lesinurad Lesinurad has been evaluated in a trial when febuxostat had been the uricosuric agent Patients did not reach target uric acid of < 5mg/dl Randomized to lesinurad 200mg, 400mg or placebo plus febuxostat Goal reached in 57% on lesinurad plus febuxostat and 47% on febuxostat only Lesinurad Headache Influenza Blood creatinine increased GERD Cardiovascular events observed in clinical trials, causal relationship not established Contraindicated in ESRD kidney transplant, dialysis patients, tumor lysis syndrome, Lesch Nyhan syndrome Xiidra (lifitegrast) Shire 2
3 Lifitegrast Lifitegrast Indicated for treatment of signs and symptoms of dry eye disease Beta 2 integrin antagonist, binds to lymphocyte function associated antigen 1 (LFA 1) Blocks interaction of LFA 1 with ligand intercellular adhesion molecule 1 (ICAM 1) May inhibit T cell adhesion to ICAM 1 and reduce secretion of inflammatory cytokines Randomized, double masked trials over 12 weeks compared lifitegrast 5% to placebo in patients with dry eye disease Efficacy end points: change from baseline in inferior corneal staining score (ICSS) and eye dryness score (EDS) ICSS scores were not statistically different EDS improved by 36% in the treatment group and 22% in the placebo group Lifitegrast Lifitegrast Trough plasma concentrations were measurable in 19% of patients who were tested Randomized, double masked 12 week trial compared lifitegrast 5% to placebo in patients with dry eye disease Co primary end points was the mean change in the visual related function subscales and changes in the ICSS score The efficacy end point for visual related function was not met The ICSS was statistically better in the treatment group Lifitegrast Instillation site irritation Dysgeusia Reduced visual acuity 3
4 Lifitegrast Insulin glargine Instill one drop twice daily into each eye Discard single use container Remove contact lens prior to administration and wait 15 minutes following administration Long acting insulin indicated for improvement in glycemic control in adults and pediatric patients with T1DM and T2DM Recombinant human insulin analog with amino acid sequence same as that of Lantus Insulin glargine stimulates peripheral glucose uptake and inhibits hepatic glucose production Insulin glargine ph of product in the vial is 4 Maximum insulin concentration in 12 hours, no pronounced peak Serum insulin levels decline to baseline by 24 hours Drug interactions: ACE inhibitors, ARB s; atypical antipsychotics, corticosteroids, niacin, protease inhibitors, alcohol, beta blockers, albuterol Insulin glargine Basaglar (insulin glargine injection) Boehringer Ingelheim/Lilly Basaglar compared to another insulin glargine product, 24 week open label study in adult and pediatric patients with inadequately controlled T1DM Insulin lispro used for fast acting glucose control Baseline HgbA1c : 7.75% vs 7.79% HgbA1c adjusted mean change from baseline: 0.35% vs 0.46% (non inferior) Proportion with HgbA1c < 7%: 43% vs. 32% 4
5 Insulin glargine Review questions for self assessment: A double blind, active control study involving patients with T2DM over 24 weeks has compared the glucose lower effect of Basaglar plus oral antidiabetic medications to another insulin glargine product plus oral medication 60% were insulin naïve at the time of entry into the study Baseline HgbA1c was 8.35% and 8.31% Change in HbgA1c was 1.3% vs. 1.3% Proportion of patients achieving HgbA1c < 7% was 48% vs. 52% Which of the following should also be in the medication profile of a patient receiving Zurampic (lesinurad)? Colchicine Allopurinol Probenecid High dose aspirin Insulin glargine Hypoglycemia Hypertension Sinusitis Cataract Bronchitis Answer allopurinol Insulin glargine Individualize dose Administer subcutaneously one daily, any time of day but at the same time every day Do not mix with any other insulin in the same syringe Maximum 80 units per injection Discard 28 days after first start using a KwikPen 5
6 Lixisenatide Adlyxin (lixisenatide) Sanofi Lixisenatide 20mcg compared to placebo over 12 weeks: HgbA1c 0.83% vs. 0.18%; FGP change 15mg/dl vs. 1.4mg/dl Lixisenatide 20mcg added to metformin compared to metformin plus placebo: HgbA1c 0.72% vs 0.26%; FPG change 16mg/dl vs. 7.2mg/dl Lixisenatide 20mcg added to basal insulin plus metformin compared to basal insulin/metformin/placebo: HgbA1c 0.71% vs. 0.34% Lixisenatide compared to liraglutide over 24 weeks, added to metformin; additional reduction in HgbA1c 1.21% for lixisenatide vs. 1.83% for liraglutide Lixisenatide GLP 1 Receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus GLP 1 agonist effect increases glucose dependent insulin release, decreases glucagon secretion and slows gastric emptying Lixisenatide Cardiovascular safety has been examined in a double blind, placebo controlled trial T2DM with history of acute coronary syndrome in past six months (n=6068) Received lixisenatide 20mcg daily or placebo plus standard diabetes medications Median observation time 25 months Primary composite CV endpoint reached in 13.4% in the lixisenatide group and 13.2% in the control group Lixisenatide Lixisenatide Peak concentration hours after injection Eliminated by GFR and proteolytic degradation Half life 3 hours Increased levels in patients with decreased renal function Drug interactions: delays in gastric emptying may change absorption pattern of some drugs give acetaminophen or antibiotics one hour before, OCP s one hour before or 11 hours after Nausea Vomiting Headache Diarrhea Dizziness 6
7 Insulin glargine/lixisenatide Initial dose 10mcg subcutaneously once daily for 14 days On day 15, increase dose to 20mcg once daily Combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM inadequately controlled on basal insulin or lixisenatide Insulin glargine lowers blood glucose by stimulating peripheral glucose uptake Lixisenatide is a GLP 1 receptor agonist that increases glucosedependent insulin release, decreases glucagon secretion and slows gastric emptying Insulin glargine/lixisenatide Insulin glargine released at rates similar to single ingredient product Lixisenatide in the combination has lower Cmax and comparable AUC to single ingredient product Half life insulin glargine 12 hours, lixisenatide 3 hours Drug interactions: usual insulin precautions, with lixisenatide precautions regarding delayed gastric emptying Insulin glargine/lixisenatide Soliqua 100/33 (Insulin glargine/lixisenatide) Sanofi Open label, randomized parallel group trial compared iglarlixi to insulin glargine only and lixisenatide only Patients had been treated at least 3 months with or without a second oral agent but had inadequate glycemic control All patients stayed on metformin during run in and through the 30 week study Mean baseline HgbA1c was 8.1%, doses titrated to achieve a FPG of mg/dl Maximum dose iglarlixi 60units/20mcg, insulin glargine 60 units, lixisenatide 20mcg 7
8 Insulin glargine/lixisenatide After 30 weeks, changes in HgbA1c were, 1.6%, 1.3% and 0.9% Patients with HgbA1c < 7%: 73.7%, 59.4% and 33% Change in body weight: 0.3kg, +1.1kg and 2.3kg Insulin glargine/lixisenatide Hypoglycemia Nasopharyngitis Diarrhea Upper respiratory infection Headache Zinplava (bezlotoxumab) Merck Insulin glargine/lixisenatide Bezlotoxumab Start with iglarlixi dose of 15 units if on less than 30 units of basal insulin per day or lixisenatide; give within one hour prior to first meal of the day If patient has been on units of glargine, start with iglarlixi 30 units per day Maximum iglarlixi dose is 60 units per day Titrate up or down by 2 4 units each week to achieve the desired result Indicated to reduce the recurrence of C. difficile in patients receiving antibacterial therapy for C. difficile who are at high rick for C. difficile infection recurrence Monoclonal antibody designed to bind to C. difficile toxin B Prevents binding of toxin B to colonic cells This monoclonal antibody binds to the B2 region of the combined repetitive oligopeptide (CROP) on toxin B 8
9 Bezlotoxumab Bezlotoxumab Elimination half life 19 days Metabolized by catabolism No meaningful differences found related to use in patients with impaired renal or hepatic function, no differences based on advanced age Nausea Pyrexia Headache Infusion related reactions Heart failure Bezlotoxumab Bezlotoxumab Evaluated in two randomized, double blind, placebo controlled trials All patients received standard of care antibiotics for treatment of CDI In study 1 patients were randomized to: (1) actoxumab (2)bezlotoxumab (3) actoxumab plus bezlotoxumab or (4) placebo Actoxumab arm stopped early (safety and efficacy concerns) Primary evaluation end point: recurrence of CDI over 12 week observation period 25.9%, 16.4%, 15.9% and 27.6% respectively Secondary end point: global cure 47%, 60%, 58% and 55% 10mg/kg, infused over 60 minutes Bezlotoxumab Similar trial design but actotoxumab only arm dropped Follow up period extended to 12 months CDI recurrence rates: bezlotoxumab 15.7%, actotoxumab plus bezlotoxumab 14.9% and placebo 25.7% Global cure rates: bezlotoxumab 66%, actotoxumab plus bezlotoxumab 57% and placebo 52% 9
10 Eucrisa (crisaborole) Anacor (A) Childhood atopic dermatitis One of the hallmarks of atopic dermatitis is lichenification in the flexural regions as shown in this picture. Note the thickening of the skin with exaggerated skin lines and erosions. (B) Atopic dermatitis in black child. Pruritic follicular papules on posterior leg. Follicular eczema pattern is more common in African and Asian children. Source: Eczema/Dermatitis, Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 7e Citation: Wolff K, Johnson R, Saavedra AP. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 7e; 2013 Available at: Accessed: January 30, 2017 Copyright 2017 McGraw-Hill Education. All rights reserved Crisaborole Crisaborole A phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older Increases cyclic AMP levels which suppresses release of cytokines Changes downstream regulation of nuclear factor kappa b and nuclear factor of activated T cell signaling pathways Mean plasma concentration after eight days of application: 127ng/ml 97% bound to plasma protein Hydrolyzed to inactive metabolites Renal excretion Drug interactions: not inducers or inhibitors of CYP system Crisaborole Childhood atopic dermatitis A typical localization of atopic dermatitis in children is the region around the mouth. In this child, there is lichenification and fissuring and crusting. Randomized double blind, vehicle controlled trials 29 days duration Patients with atopic dermatitis covering 5 95% of treatable body surface area, age range 2 79 years Baseline severity scores (Investigator's Static Global Assessment) ISGA score 2 in 38.5% and 61.5% with ISGA score of 3 After 29 days a score of clear (0) or almost clear(1) was reached in 32%on treatment vs. 25% using vehicle in study 1 and 31% vs 18% in study 2 Pruritus improvement by one grade or more shown in 63% vs. 53% Source: Eczema/Dermatitis, Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 7e Citation: Wolff K, Johnson R, Saavedra AP. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 7e; 2013 Available at: Accessed: January 30, 2017 Copyright 2017 McGraw-Hill Education. All rights reserved 10
11 Crisaborole Application site pain Answer Lixisenatide Crisaborole Apply a thin layer twice a day to affected areas Review questions for self assessment Which of the following is most likely to have afavorable impact on weight loss in a patient with T2DM? Insulin glargine Lixisenatide Pioglitazone Insulin glargine combined with lixisenatide Zepatier (elbasvir/grazoprevir) Merck 11
12 Elbasvir/grazoprevir Elbasvir/grazoprevir Indicated as a fixed dose combination for HCV genotypes 1 and 4, with and without ribavirin Elbasvir is an inhibitor of NS5A Grazoprevir is an inhibitor of NS3/4A Inhibits proteolytic activity of genotypes 1a, 1b and 4 Contraindicated in moderate or severe hepatic impairment Drug interactions: contraindicated with phenytoin, carbamazepine, rifampin, St. Johns wort, efavirenz, atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cyclosporine Naming Conventions Regarding Antivirals NS5B polymerase inhibitors NS5A inhibitors BUVIR (e.g. sofosbuvir, dasabuvir) ASVIR (e.g. ledipsavir, ombitasvir, velpatasvir) Elbasvir/grazoprevir Placebo controlled trial evaluating elbasvir/grazoprevir once daily in patient with HCV genotypes 1 or 4, with or without cirrhosis Placebo group received active drug in a deferred fashion Patients treated for 12 weeks, therapeutic end point was SVR12 End point reached in 95% Similar rates for 1a and 1b, cirrhosis and non cirrhosis NS3/4A protease inhibitors PREVIR (e.g. simeprevir, paritaprevir) Elbasvir/grazoprevir Elbasvir/grazoprevir Elbasvir peak in 3hrs., grazoprevir peak in 2 hrs. Can be taken without regard to food Both are extensively protein bound Metabolism primarily by CYP 3A Half life: elbasvir 24 hours, grazoprevir 31 hours Eliminated in feces Higher levels in female, geriatric and Asian population Double blind, placebo controlled trial; patients with genotype 1 with and without cirrhosis Patients with CKD stage 4 and 5 (including HD) One tablet daily for 12 weeks SVR 12 for the treatment group 95% SVR in patients with cirrhosis 86% 12
13 Elbasvir/grazoprevir Randomized, open label trial compared elbasvir/grazoprevir once daily for 12 weeks to elbasvir/grazoprevir plus ribavirin for 16 weeks Patient with genotype 1 or 4; with or without cirrhosis, with or without HCV/HIV1 coinfection Patients had failed PegIFN plus RBV therapy previously SVR12 for genotype 1 after 12 weeks of elbasvir/grazoprevir 94% SVR12 after 16 weeks of elbasvir/grazoprevir plus RIB was 97% 5% relapse rate in 12 week group Elbasvir/grazoprevir Fatigue Headache Nausea Usual ribavirin concerns if added Epclusa (sofosbuvir/velpatasvir) Gilead Elbasvir/grazoprevir Sofosbuvir/velpatasvir Genotype 1a, treatment naïve, PegIFN experienced without baseline polymorphism: one tablet daily for 12 weeks Genotype 1a, treatment naïve, PegIFN experienced with baseline polymorphism: one tablet daily for 16 weeks Genotype 1b, treatment naïve or PegIFN/RBV experienced: one tablet daily for 12 weeks Genotype 1a or 1b: Peg/IFN/RBV/NS3/4A protease inhibitor experienced: elbasvir/grazoprevir plus ribavirin for 12 weeks Genotype 4, treatment naïve: one tablet daily for 12 weeks Genotype 4, PegIFN/RBV experienced: elbasvir/grazoprevir plus ribavirin for 16 weeks Indicated for treatment of adult patients with hepatitis C genotype 1,2,3,4,5 or 6 Sofosbuvir is an NS5B polymerase nucleotide inhibitor Velpatasvir is an NS5A inhibitor 13
14 Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir Sofosbuvir 65% protein bound, velpatasvir > 99.5% protein boundd Increased absorption when taken with high fat meal Sofosbuvir metabolized by cathepsin A to GS ; velpatasvir metabolized by CYP system Half life: GS hours, velpatasvir 15 hours Excretion sofosbuvir 80% in the urine, velpatasvir 94% in the feces A randomized, open label trial has compared 12 weeks of sofosbuvir/velpatasvir to 24 weeks of treatment with sofosbuvir plus ribavirin in patients with genotype 3 HCV infection Patients were also stratified on the basis of cirrhosis and prior treatment experience The SVR 12 was 95% for the sofosbuvir/velpatasvir group and 80% for the SOF + RBV group. Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir Drug interactions: velpatasvir inhibits P gp (increased levels of dabigatran, digoxin, rosuvastatin, tenofovir); velpatasvir has low solubility in low acid environment; efavirenz and carbamazepine reduce sofosbuvir/velpatasvir levels; sofosbuvir is a P gp substrate, reduced levels when given with CYP inducers; important interaction with amiodarone serious symptomatic bradycardia (particularly in those already taking beta blockers) Sofosbuvir/velpatasvir has been evaluated in a open label trial in patients with genotype 1,2,3,4,5 or 6 HCV and decompensated cirrhosis Patients received (1)sofosbuvir/velpatasvir only for 12 weeks, (2)sofosbuvir/velpatasvir plus ribavirin for 12 weeks or (3)24 weeks of sofosbuvir/velpatasvir only Best results numerically were with the sofosbuvir/velpatasvir plus ribavirin for 12 weeks (SVR 12 = 94%, 3% virologic failure) Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir has been evaluated in a randomized, doubleblind, placebo controlled trial that evaluated 12 weeks of treatment in patients with genotype 1,2,4,5 or 6 HCV infection Primary outcome of evaluation was SVR 12. The end point was reached in 98% with genotype 1a, 99% with genotype 1b, 100% with genotype 2, 100% with genotype 4, 97% with genotype 5 and 100% with genotype 6. None of the patients receiving placebo achieved the end point. Headache Fatigue Nausea Asthenia Insomnia Ribavirin adverse effects and precautions if added to treatment 14
15 Sofosbuvir/velpatasvir Patiromer One tablet (sofosbuvir 400mg and velpatasvir 100mg) taken once daily with or without food for 12 weeks Patients with decompensated cirrhosis one tablet daily plus ribavirin for 12 weeks Patiromer is a cation exchange polymer indicated for treatment of hyperkalemia A sodium free, non absorbed cation exchange polymer (SNAP) Contains calcium sorbitol counter ion Binds potassium in the lumen of the GI tract Patiromer Not systemically absorbed Excreted in feces No dose adjustments based on renal or hepatic function Initial serum potassium reduction seen at 7 hours Drug interactions: (potential risk) separate patiromer 3 hours before or after amlodipine, cinaclet, ciprofloxacin, clopidogrel, furosemide, levothyroxine, lithium, metformin, metoprolol, trimethoprim, verapamil, warfarin Patiromer Veltassa (patiromer) Relypsa Efficacy has been evaluated in two part randomized withdrawal study Hyperkalemia patients with CKD Patiromer dose titrated based on potassium level at baseline After four weeks, mean decrease was 0.65mEq/L (average baseline potassium 5.31mEq/L) Mean decrease 1.23mEq/L (average baseline potassium was 5.74mEq/L Patients at target were re randomized to (A) continue patiromer or (B) change to placebo After four weeks: patiromer stayed same, placebo group had potassium increase of 0.72mEq/L 15
16 Patiromer Review questions for self assessment Constipation Hypomagnesemia Diarrhea Nausea Abdominal discomfort Flatulence Which patient group would need ribavirin added to Epclusa for treatment of hepatitis C? Decompensated cirrhosis Pregnant Genotype 3 Previous treatment failures Patiromer Answer Start with 8.4gm once daily Pour packet into 30ml water and stir Add 60ml more water and stir Drink it immediately Administer with food Do not take in its powdered form Decompensated cirrhosis Nucala (mepolizumab) Glaxo 16
17 Mepolizumab Mepolizumab Add on maintenance treatment of severe asthma in patients 12 years of age and older who have an eosinophilic phenotype Interleukin 5 antagonist Binds to the alpha chain of the IL 5 receptor complex on the eosinophil cell surface Reduction in eosinophils in sputum and blood with selective inhibition of eosinophilic inflammation Mepolizumab has been evaluated in a randomized 32 week, active control trial involving patients with recurrent asthma exacerbations and eosinophilic inflammation despite high dose inhaled corticosteroids with or without oral steroids Patients received either mepolizumab 75mg IV, mepolizumab 100mg SQ or placebo every four weeks Primary end point of evaluation was the frequency of exacerbation requiring steroids or the need for hospitalization Exacerbation rates after 32 weeks were: 0.93 exacerbations per year in the 75mg group, 0.83 exacerbations per year in the 100mg group and 1.74 exacerbations per year in the placebo group Patients who enrolled on the basis of historical blood eosinophil count of 300 cells per microliter or greater in the past 12 months but had a baseline blood eosinophil count of less than 150 cells per microliter had no exacerbation benefit compared to placebo Mepolizumab Mepolizumab Subcutaneous administration produces bioavailability of 80% 2 fold accumulation at steady state Small volume of distribution Degraded by widely available proteolytic enzymes Half life days No specific dosing changes recommended based on race, gender, age, renal or hepatic impairment Drug interactions: no studies conducted Headache Injection site reaction Back pain Fatigue Systemic allergic hypersensitivity Herpes zoster injections Mepolizumab Mepolizumab Evaluated in a multi center, double blind, placebo controlled study on patients with severe asthma who had one of the following: sputum eosinophil count > 3%, fractional exhaled nitric oxide concentration 50ppb, peripheral blood eosinophil count 300 cells/microliter or rapid deterioration of asthma control after a dose reduction in inhaled or oral steroids Patients received intravenous mepolizumab doses of 75mg, 250mg, 750mg or placebo every four weeks for 52 weeks Primary end point of evaluation was the rate of clinically significant asthma exacerbations Exacerbation rates were: 1.24 per patient per year, 1.46 per patient per year, 1.15 per patient per year and 2.4 per patient per year in the placebo group 100mg SQ once every four weeks Does not treat acute bronchospasm Do not discontinue systemic or inhaled corticosteroids abruptly Treat patient with pre existing helminth infections before starting mepolizumab; if patient becomes infected while being treated and does not respond, discontinue mepolizumab until parasite resolved 17
18 Exondys 51 (eteplirsen) Sarcepta Eteplirsen Eteplirsen Antisense oligonucleotide indicated for treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping Labeling states: clinical benefit of eteplirsen has not been established. Synthetic strand of nucleic acid that binds to exon 51 of the dystrophin gene producing skipping of the exon during RNA transcription This allows formation of a truncated partially functional dystrophin protein. Peak concentration near the end of the infusion Protein binding 6 17% No dose accumulation with weekly doses Primarily renal elimination Half life 3 4 hours Dystrophin level after 180 weeks of treatment 0.93% of the dystrophin level in a healthy person Drug interactions: in vitro data indicates lack of drug interactions due to protein binding, cytochrome P450 or drug transporter interactions 18
19 Eteplirsen Eteplirsen Eteplirsen was evaluated in three trials of boys with DMD and gene deletion 51 First trial (n=12) looked at two doses (30mg/kg and 50mg/kg) compared to placebo and measured dystrophin levels as a primary outcome Clinical outcome was a 6 minute walk test after 24 weeks Changes in dystrophin levels correlated with dose size Six minute walk test was not different between the treatment group and the placebo group 30mg/kg once weekly as a minute IV infusion Eteplirsen Review questions for self assessment The same patients (n=12) were re randomized in an open label continuation study for an additional four years Patients received either 30mg/kg/week or 50mg/kg/week (n=6 in each group) The mean dystrophin level was 0.16% of normal at baseline and 0.44% of normal after week 48 The primary clinical efficacy outcome was the six minute walk test Study failed to provide evidence of clinical benefit of eteplirsen compared to the external control group. Which of the following medications would be least likely to necessitate use of Veltassa (patiromer) in a CKD patient? Spironolactone Losartan Metoprolol Lisinopril Eteplirsen Balance disorder Vomiting Contact dermatitis Answer metoprolol 19
20 Pimavanserin Peak concentration 6 hours after dosing Primarily hepatic metabolism by CYP 3A4 and CYP 3A5 to an active metabolite, AC 279 Primarily fecal elimination of the AC 279 desmethylated metabolite Half life 57 hours parent compound, 200 hours for AC 279 Drug interactions: strong CYP 3A4 inhibition (e.g. ketoconazole) reduce pimavanserin dose by half; strong CYP 3A4 inducers increased pimavanserin dose may be needed; caution when used with drugs known to cause prolongation of QT interval Pimavanserin Nuplazid (pimavanserin) Acadia Pimavanserin has been evaluated in a randomized, multi center, double blind, parallel group, placebo controlled trial involving Parkinsons disease patients who had psychotic symptoms for at least a month prior to entry into the trial Patients had to have an MMSE of at least 21 points out of 30 and no delirium Patients received a two week non pharmacological brief psychosocial therapy to help elicit a placebo response ahead of baseline Patients were randomized to pimavanserin 40mg/day or placebo Primary end point of evaluation was the change in baseline in the Scale for Assessment of Positive Symptoms (SAPS) hallucination or delusions global item measured on day 43 Secondary end points were Clinical Global Impression Severity (CGI S) and improvement (CGI I) Primary end point showed a 37% change from baseline while the placebo group showed a 14% change (p=0.0006) Secondary end points also showed significant improvement from baseline compared to the placebo group. Pimavanserin Pimavanserin Atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis Inverse agonist and antagonist with high affinity for 5HT2a receptors. Has low affinity for 5HT2c receptors and no affinity at dopaminergic, histaminergic, cholinergic or adrenergic receptors Peripheral edema Nausea Confusional state Black box warning regarding risk of death in dementia related psychosis 20
21 Pimavanserin Plecanatide Take two 17mg tablets daily Can take with or without food Guanylate cyclase C agonist indicated for treatment of chronic idiopathic constipation Stimulates guanylate cyclase C receptor on luminal surface of intestinal epithelium Activation increases concentrations of cyclic GMP Stimulates secretion of chloride and bicarbonate into intestinal lumen Plecanatide Minimally absorbed, negligible systemic availability Metabolized in the GI tract by proteolysis No excretion studies conducted Drug interactions: plecanatide not inhibited or induced by cytochrome P450 or P gp Plecanatide Trulance (plecanatide) Synergy Efficacy of plecanatide has been established in two double blind, placebocontrolled, randomized trials of 12 weeks duration involving patients with chronic idiopathic constipation Patients received either plecanatide 3mg once daily or placebo At baseline, patients reported three or fewer defecations per week The efficacy of plecanatide was assessed using responder analysis and change from baseline in CSBM and SBM end points A responder was defined as at least 3 CSBM s in a given week and increase of at least one CSBM from baseline for at least 9 out of the 12 week treatment period and at least 3 of the last 4 weeks of the study Responder rates study 1: 21% vs. 10%. Responder rates study 2: 21% vs. 13% 21
22 Plecanatide Diarrhea Answer >$10 per day Plecanatide 3mg orally once daily Can be crushed and mixed with applesauce or water for patients with swallowing difficulty Review questions for self assessment Based on current pricing, the cost per day of treating signs or symptoms of dry eye with Xiidra (lifitegrast) will be: $1 per day $5 per day $10 per day >$10 per day 22
2017 New Drug Update
2017 New Drug Update Tom Frank, Pharm.D., BCPS Director of Research and Education UAMS Northeast I have no conflicts of interest to report 1 Objectives Discuss trends in drug development Describe indications,
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationZepatier. (elbasvir, grazoprevir) New Product Slideshow
Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength
More information2017 New Drug Update. Robert Lipsy PharmD, FASHP Southwest Clinical Pharmacy Seminar February 25 and Tucson, Az. Conflicts of Interest None
2017 New Drug Update Robert Lipsy PharmD, FASHP Southwest Clinical Pharmacy Seminar February 25 and 26 2017 Tucson, Az. Conflicts of Interest None New Drugs 2016 1 New Drugs December 2016 New Drugs December
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationZurampic. (lesinurad) New Product Slideshow
Zurampic (lesinurad) New Product Slideshow Introduction Brand name: Zurampic Generic name: Lesinurad Pharmacological class: URAT1 inhibitor Strength and Formulation: 200mg; tablets Manufacturer: Ironwood
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationNuplazid. (pimavanserin) New Product Slideshow
Nuplazid (pimavanserin) New Product Slideshow Introduction Brand name: Nuplazid Generic name: Pimavanserin Pharmacological class: Atypical antipsychotic Strength and Formulation: 17mg; tablets Manufacturer:
More informationSoliqua 100/33. (insulin glargine, lixisenatide) New Product Slideshow
Soliqua 100/33 (insulin glargine, lixisenatide) New Product Slideshow Introduction Brand name: Soliqua 100/33 Generic name: Insulin glargine (rdna origin), lixisenatide Pharmacological class: Human insulin
More informationAdlyxin. (lixisenatide) New Product Slideshow
Adlyxin (lixisenatide) New Product Slideshow Introduction Brand name: Adlyxin Generic name: Lixisenatide Pharmacological class: Glucagon-like peptide-1 (GLP-1) receptor agonist Strength and Formulation:
More informationXultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow
Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationNew Drug Update Joe Strain, Pharm.D. SDSU College of Pharmacy Rapid City Regional Hospital
New Drug Update 2016 Joe Strain, Pharm.D. SDSU College of Pharmacy Rapid City Regional Hospital Learning Objectives Upon successful completion of this activity, the audience should be able to: Identify
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationHepatitis C: Module Options for genotype 1a and 1b pros and cons
Drug Regimen HCV genotype Pros Cons Sofosbuvir 400mg + ledipasvir 90mg, orally, Sofosbuvir 400mg, orally, + daclatasvir 60mg, orally Elbasvir 50mg + grazoprevir 100mg, orally Once- single pill regimen.
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationTreating Hepatitis C in Patients with Advanced Renal Disease
Treating Hepatitis C in Patients with Advanced Renal Disease Seyed Moayed Alavian M.D. Professor of Medicine, Hepatologist alavian@thc.ir Hemodialysis Patients hemodialysis Preventive Strategies Strict
More informationUpdates in the Treatment of HCV
Updates in the Treatment of HCV Misty Miller, Pharm.D., BCPS, AAHIVP Associate Professor University of Oklahoma College of Pharmacy September 21 st, 2018 Overview HCV Review and Definitions HCV Genotypes
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationONCE-DAILY DOSING WITH NUPLAZID
YOUR GUIDE TO ONCE-DAILY DOSING WITH NUPLAZID NUPLAZID (pimavanserin) is the first and only FDAapproved treatment for hallucinations and delusions associated with Parkinson s disease psychosis 1 Indication
More informationNew Drug Update 2017 Brooke Roe, PharmD, BCPS Katie Wenstrom, PharmD
New Drug Update 2017 Brooke Roe, PharmD, BCPS Katie Wenstrom, PharmD Objectives: 1. Identify significant therapeutic agents that were granted U.S. Food and Drug Administration approval in the past year
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationNew therapeutic agents marketed in 2016: Part 1 Daniel A. Hussar and Eric F. Hussar
CPE New therapeutic agents marketed in 2016: Part 1 Daniel A. Hussar and Eric F. Hussar Abstract Objective: To provide information about the most important properties of new FDA-approved therapeutic agents
More informationLimitations of Use: (1) Duzallo is not recommended for the treatment of asymptomatic hyperuricemia.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.63 Subject: Duzallo Page: 1 of 5 Last Review Date: December 8, 2017 Duzallo Description Duzallo (lesinurad
More informationWARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV
There are recent changes to the Prescribing Information (PI) and Patient Information (PPI) for ZEPATIER (elbasvir and grazoprevir) 50 mg/100 mg tablets. The class labeling revisions now included in the
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationEpclusa (Sofosbuvir/Velpatasvir) for HIV/HCV
Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationNew Drug Update: 2018
New Drug Update: 2018 Wesley Lindsey, Pharm.D. Associate Clinical Professor Auburn University Harrison School of Pharmacy Drug Information and Learning Resource Center Bio Undergraduate: University of
More informationBrand Name: Epclusa. Generic Name: sofosbuvir and velpatasvir. Manufacturer 5 : Gilead Sciences, Inc.
Brand Name: Epclusa Generic Name: sofosbuvir and velpatasvir Manufacturer 5 : Gilead Sciences, Inc. Drug Class 1,2 : Antivirals, Anti-hepatitis agents 1,2 Uses: 1,2,3,4,5 Labeled Uses: The combination
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationPRUCAPLA Tablets (Prucalopride)
Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium
More informationHEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg)
Published on: 3 Jul 2017 HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg) Black Box Warning Risk of Hepatitis B Virus Reactivation in Patients Co-Infected with HCV And HBV Test all patients for
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationMAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW
MAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW Introduction Brand name: Mavyret Generic name: Glecaprevir, pibrentasvir Pharmacological class: HCV NS3/4A protease inhibitor + HCV NS5A inhibitor
More informationDisclosures. Technician Objectives. Pharmacist Objectives. New Drug Stats. New Drug Updates. New Drugs & Disease States 8/31/2016
Disclosures New Drug Updates Both presenters have nothing to disclose. Lalita Prasad Reddy, PharmD, MS, BCACP, BCPS, CDE Clinical Assistant Professor Chicago State University College of Pharmacy Diana
More informationObjectives. Objectives. Introduction. Hepatitis A. Hepatitis B. At the end of the presentation, pharmacy technician participants will be able to:
Objectives A Revolution in Medicine: Advances in the Treatment of Hepatitis C Infection Spencer H. Durham, Pharm.D., BCPS (AQ ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison
More informationParent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins
Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic
More informationPHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationT max V d t 1/ hours 100 L 3 hours
Brand Name: Adlyxin Generic Name: lixisenatide Manufacturer: Sanofi-Aventis U.S. LLC 1 Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist 2,3,4 Uses: Labeled Uses 1,2,3,4,5 : Type 2 diabetes
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationDisclosures. Pharmacist Objectives. Technician Objectives. Definitions. Definitions. New Drug & Therapies Update 11/2/17. First-in-Class Drug
Disclosures New Drug & Therapies Update No relevant conflicts of interest to disclose No off-label indications will be presented Nicholas Cox, PharmD November 4, 2017 Intensive Outpatient Clinic, University
More informationVELTASSA (patiromer) oral suspension
VELTASSA (patiromer) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationSystem): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes
Volume 30, Issue 2 November 2014 Afrezza (Technosphere Insulin Inhalation System): Rapid-Acting Inhaled Insulin for the Treatment of Diabetes Merly Suarez, PharmD Candidate D P PharmacodynamicsandPharmacokinetics
More informationSofosbuvir and Velpatasvir. (Systemic) Cautions. Uses. Dosage and Administration
Sofosbuvir and Velpatasvir (Systemic) HCV antiviral; fixed combination containing sofosbuvir (nucleotide analog HCV NS5B polymerase inhibitor) and (HCV NS5A replication complex inhibitor [NS5A inhibitor]).
More informationGilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018
Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 October 11, 2018 3:24 PM ET -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationPRODUCT CIRCULAR. Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS II. INDICATIONS III. DOSAGE AND ADMINISTRATION PAK-CZR-T
PRODUCT CIRCULAR Tablets I. THERAPEUTIC CLASS, the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1 ) antagonist. also provides a reduction in
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationSILOFAST Capsules (Silodosin)
Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. ZEPATIER 50 mg of elbasvir and 100 mg of grazoprevir
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION ZEPATIER 50 mg of elbasvir and 100 mg of grazoprevir Read this carefully before you start taking ZEPATIER and each time
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationZURAMPIC (lesinurad) oral tablet
ZURAMPIC (lesinurad) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with
More informationElbasvir and Grazoprevir. (Systemic) Uses. Dosage and Administration
Elbasvir and Grazoprevir (Systemic) Antiviral; fixed combination containing elbasvir (HCV NS5A replication complex inhibitor [NS5A inhibitor]) and grazoprevir (HCV NS3/4A protease inhibitor). Class: 8:18.40.24
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationPHARMACEUTICAL INFORMATION AZILSARTAN
AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-
More informationOutpatient Pharmacy Effective Date: August 15, 2014
Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationDrug Class Review Monograph GPI Class 12 Antivirals
Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationClinical Pearls in Renal Medicine
Clinical Pearls in Renal Medicine Joel A. Gordon MD Professor of Medicine Nephrology Division Staff Physician Kidney Disease and Blood Pressure Clinic Disclosures None of my financial holdings will have
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More informationVIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015
VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research
More informationNew Drugs for the Primary Care Provider: What You Need to Know
4:00 4:35 pm New Drugs for the Primary Care Provider: What You Need to Know SPEAKER Gerald W. Smetana, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationCinqair. (reslizumab) New Product Slideshow
Cinqair (reslizumab) New Product Slideshow Introduction Brand name: Cinqair Generic name: Reslizumab Pharmacological class: Interleukin-5 antagonist Strength and Formulation: 100mg/10mL; solution for IV
More informationCE Prn. Pharmacy Continuing Education from WF Professional Associates
CE Prn Pharmacy Continuing Education from WF Professional Associates W-F Professional Associates, Inc. 400 Lake Cook Road, Suite 207 Deerfield, Illinois 60015 847.945.8050 www.wfprofessional.com (Email)
More information